Open an account

Caris Life Sciences

CAI · NASDAQ

$31.11+$0.40 (+1.30%)TodayMarket closed ·
Prev close $30.71

About CAI

Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. The company is headquartered in Irving, Texas and currently employs 1,846 full-time employees. The company went IPO on 2025-06-18. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Employees
1,846
Headquarters
Irving, Texas
Listed
Jun 18, 2025
Sector
Health Care
Industry
Biotechnology
Website
carislifesciences.com

CAI key statistics

Market cap
8.68B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
4.22M
Volume
3.54M
Open price
$30.71
High today
$31.56
Low today
$30.10
52 Week high
$33.13
52 Week low
$14.19

Caris Life Sciences (CAI) at a glance

Caris Life Sciences (CAI) last traded at $31.11, with a market cap of 8.68B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $30.10 and $31.56. The current price is 3.4% above the day's low and 1.4% below its high.

Volume so far is 3.54M shares, in line with the average of 4.22M shares a day.

Over the past year Caris Life Sciences has ranged from $14.19 to $33.13, and now sits 89% of the way up that range.

Caris Life Sciences met or beat analyst EPS estimates in 3 of the last 5 quarters. In Q2 FY26 it reported $0.00 per share against an estimate of $0.0101.

The average analyst price target is $28.31, 9.0% below the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

64%of 11 analyst ratings say Buy
  • Buy63.6%
  • Hold36.4%
  • Sell0.0%
Price target · 14 analystsAvg $28.31
Low
$22.22
Now
$31.11
High
$36.75

CAI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 5 quarters, by 338.8% on average.

  1. Q2 FY25: reported -$7.97 per share against an estimate of -$0.202
  2. Q3 FY25: reported $0.082 per share against an estimate of -$0.2121
  3. Q4 FY25: reported $0.28 per share against an estimate of $0.0319
  4. Q1 FY26: reported $0.00 per share against an estimate of -$0.0221
  5. Q2 FY26: reported $0.00 per share against an estimate of $0.0101

CAI news

  • Press releasePRNewswire

    Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection

  • Press releasePRNewswire

    Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

  • Press releasePRNewswire

    Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026

  • Piero Cingari

    10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today

  • Press releasePRNewswire

    Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect

  • Press releasePRNewswire

    Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer

  • Press releasePRNewswire

    Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

Similar companies

Companies in the same industry as Caris Life Sciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.